换一批
换一批TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.
第一作者：
Jina,Yun
第一单位：
Department of Internal Medicine, Division of Hemato-Oncology, Soonchunhyang University Bucheon Hospital, 170 Jomaru-ro, Wonmi-gu, Bucheon-si 14584, Gyeonggi-do, Korea.
作者：
主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗代谢药, 抗肿瘤(Antimetabolites, Antineoplastic);阿扎胞苷(Azacitidine);DNA甲基化(DNA Methylation);DNA结合蛋白质类(DNA-Binding Proteins);双加氧酶类(Dioxygenases);女(雌)性(Female);人类(Humans);男(雄)性(Male);微RNAs(MicroRNAs);中年人(Middle Aged);突变(Mutation);骨髓增生异常综合征(Myelodysplastic Syndromes);原癌基因蛋白质类(Proto-Oncogene Proteins);存活率(Survival Rate);治疗结果(Treatment Outcome);青年人(Young Adult)
DOI
10.3390/cimb43020065
PMID
34449560
发布时间
2022-07-16
- 浏览2
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
